Publications
325
Citations
21,770
Est. group size
—
Recurring co-author estimate
Active years
42
Publishing since 1985
Lois B. Travis studies the long-term health effects experienced by cancer survivors, especially people treated for testicular cancer. A major focus is understanding why the chemotherapy drug cisplatin causes side effects like hearing loss, ringing in the ears (tinnitus), and nerve damage, and how a person's genetic makeup influences their risk of these problems. This work combines cancer epidemiology (studying patterns of disease in populations) with pharmacogenomics (how genes affect drug responses).
Publication activity was steady at roughly 10 per year through the late 2010s and surged in 2023 (partly from supplementary dataset entries), with fewer records logged for the most recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Impact of Population Pharmacogenomics on Cisplatin‐Induced Neurotoxicities in Testicular Cancer Survivors
Cancer Medicine · 2025
- Abstract 4357: Disparities in neurotoxicities in cisplatin-treated cancer patients: a population pharmacogenomics approach
Cancer Research · 2025
- Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population
Frontiers in Pharmacology · 2025
- Abstract C051: Impact of population pharmacogenomics on cisplatin-induced neurotoxicities
Cancer Epidemiology Biomarkers & Prevention · 2024
- Comparison of GWAS results between de novo tinnitus and cancer treatment-related tinnitus suggests distinctive roles for genetic risk factors
Scientific Reports · 2024
- The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).
Journal of Clinical Oncology · 2023
- Supplementary Table S3 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Supplementary Table S4 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Supplementary Table S5 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Supplementary Figure S3 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Supplementary Figure S1 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Supplementary Table S2 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Supplementary Figure S2 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Supplementary Figure S4 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Supplementary Table S1 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
2023
- Journal of Clinical Oncology×40
- Clinical Cancer Research×6
- JNCI Cancer Spectrum×6
- Journal of the National Comprehensive Cancer Network×3
- Cancer Medicine×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile